Ology Bioservices, Inc. Global CDMO
Corporate Overview
About Ology Bioservices, Inc.
The company was founded in 1999 as an integrated biopharmaceutical company with a focus on development and manufacturing as well as having expertise in preclinical and clinical development, formulation optimization, and CGMP manufacturing of biopharmaceutical products and medical devices.
From its early beginnings, the company’s growth was fueled through grants and contracts from both industry and several U.S. Government (USG) agencies (NIH, DoD, NCI, BARDA). Today, the company has grown to over 200 employees located in several locations across the U.S. On March 30, 2013, the Department of Defense (DoD) awarded the company and its team of partners and collaborators a contract to provide all of the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility dedicated to meeting the specific needs of the DoD. The 10-year, $400+ million contract had a base period goal for the construction of an 183,000-square-foot, state-of-the-art, BSL-3, single-use facility that the company now occupies and operates.
Ology Bio recently developed and acquired proprietary platform technologies that are used in the production of biologic products including antibodies, cell & gene therapies, proteins, and vaccines.
Ology Bioservices, Inc. has positioned itself to be one of the leading Contract Development and Manufacturing Organizations (CDMO) on a global level.
Core Capabilities
From process development, quality control testing, and CGMP manufacturing of bulk drug substances to development, scale-up, and production using our proprietary platform technologies, our goal is to manufacture only the highest quality biopharmaceutical products for our partners.
The ADM Facility
183,000 SQFT, BSL-3, cGMP, ISO 9001… Our multi-purpose and multi-product biologics and vaccine facility is designated an “Advanced Development and Manufacturing (ADM) facility.”
Partnering and Licensing
Our proprietary Vero Cell vaccine manufacturing cell line has demonstrated value for the rapid development of inactivated whole virus vaccines. Licenses to this technology are available for specific indications and markets worldwide.
Process Development
The Process Development Group can develop an entire process or optimize individual steps in an existing process to ensure the process is suitable for manufacturing in a CGMP environment.
COVID-19 Letter